An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) announced its participation at the 36th European Immunogenetics and Histocompatibility Conference from April 26-29 in Nantes, France. The company will showcase its AlloSeq portfolio for HLA typing and organ transplant monitoring, highlighting innovations in precision medicine for transplant patients.
The event will feature a symposium focused on innovative pre- and post-transplant solutions, moderated by Curtis Lind, with discussions led by various experts on HLA typing and chimerism analysis. CareDx emphasizes its commitment to advancing immunogenetics and supporting the European transplant community.
The AlloSeq products aim to enhance pre- and post-transplant care, reinforcing CareDx’s leadership in the transplant genomics market.
Positive
Showcasing the AlloSeq portfolio may enhance brand visibility in Europe.
Commitment to innovation and leadership in the transplant genomics field.
Sponsoring a prominent symposium may strengthen industry connections.
Negative
None.
Posters and Symposium Highlight Utility of AlloSeq for HLA Typing, Organ Transplant Monitoring and Hematopoietic Stem Cell Monitoring
BRISBANE, Calif.--(BUSINESS WIRE)--
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase the latest developments across its AlloSeq®* portfolioduring the 36thEuropean Immunogenetics and Histocompatibility Conference taking place April 26-29 in Nantes, France.
“We look forward to participating in this meeting and presenting our latest innovations for the European transplant community with our AlloSeq* portfolio of lab products for research and clinical use pre- and post-transplantation,” said Reg Seeto, CEO and President of CareDx. “We are committed to advancing the field of immunogenetics and histocompatibility and take great pride in supporting this important event as a platinum sponsor.”
CareDx will be on hand to display its leadership in serving European laboratories, researchers, and clinicians with its best-in-class product portfolio of next-generation sequencing (NGS) based AlloSeq* products, which enables best-in-class care both pre- and post-transplantation.
For pre-transplant, CareDx offers AlloSeq Tx* HLA typing solutions. For post-transplant, CareDx offers AlloSeq HCT* chimerism testingand AlloSeq cfDNA* for labs to assess transplanted stem cells and organ health, respectively. CareDx also provides pre-transplant HLA typing and post-transplant surveillance testing for customers through its service lab in Stockholm, Sweden, for clinical research.
CareDx will sponsor a symposium “Breaking New Ground: Innovative Pre- and Post-Transplant Solutions to Improve Allograft Outcomes” on Thursday, April 27. The event will be moderated by Curtis Lind, CareDx Vice President and Head of R&D products. Panelists and topics include:
Monica Irina Dutescu M,D., Ph.D.,National HLA Laboratory, National Institute of Blood Transfusion Prof. Dr. C.T. NICOLAU Bucharest, Romania: High Resolution HLA Typing with AlloSeq Tx – the Experience of National HLA Laboratory, Bucharest.
Miguel Alcoceba Ph.D.,Department of Haematology, University Hospital of Salamanca (HUS-IBSAL) Salamanca, Spain: Comparison of Next-Generation Sequencing and Short-Tandem Repeats to Monitor Chimerism Analysis.
Olivier Aubert M.D., Ph.D.,Necker-Enfants Malades Hospital - Paris Transplant Group, Paris, France: dd-cfDNA in Allograft Rejection and Risk Assessment.
“I look forward to participating in the CareDx sponsored symposium and showing how its innovative HLA typing solutions represent a strong, efficient, and user-friendly technique for pre-transplant testing, that provides reliable, accurate results. I will also demonstrate how the use of its hybrid capture method can also provide the best coverage, high level of transplant matching and low rates of ambiguity in one product,” said Monica Irina Dutescu, M.D., Ph.D., National Institute of Blood Transfusion, Bucharest.
The following nine AlloSeq* oral presentations and posters will be presented at the meeting.
Title
First Author
Poster
Featuring AlloSeq Tx17 and Hybrid Capture
The expanded role of microRNAs in controlling the HLA class I phenotype: Relationship between the 3’ UTR and post-transcriptional Gene Regulation
Panagiotis Mallis
Oral
Detection of HLA-A and HLA-J haplotype diversity from next-generation sequencing data in commercially available samples.
Jessica Edwards
P100
Identification of the novel HLA-DPB1*02:01:68 allele in a Greek individual
Diamanto Kouniaki
P127
Identification of the novel HLA-A*01:426 allele in a Greek individual
Diamanto Kouniaki
P129
Identification of the novel HLA-A*02:09:01:04 allele in a Greek individual
Diamanto Kouniaki
P130
Featuring AlloSeq HCT
Evaluation of the Magelia for automated purification of CareDx AlloSeq HCT kit libraries in the context of post-hematopoietic stem cells transplantation chimerism assessment
Coralie Frassati
P124
Featuring AlloSeq cfDNA Assay and Software
Clinical relevance of cell-free DNA quantification and qualification during the first month after lung transplantation
Pascal Pedini
Oral
Donor specific HLA-DPw antibodies in a highly sensitized kidney transplant recipient – a case report
Dolores Hrusovar
P74
Results of the 6 Months Post-Transplant Surveillance in patients transplanted with preformed donor-specific anti-HLA antibodies (DSA) by Adding Donor-Derived Cell-Free DNA Testing
María Lasa-Lázaro
P121
*AlloSeq Tx, AlloSeq HCT and AlloSeq cfDNAare available as CE/IVD in the EU and in the U.K., and Research Use Only for the rest of the world. AlloSeq Service is available as Research Use Only. Research Use Only products are not to be used for diagnostic procedures. AlloSeq cfDNA is only available outside of the United States. For local regulatory status, please contact CareDx.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s AlloSeq* portfolio of lab products,as well as CareDx’s leading participation at the 36th European Immunogenetics and Histocompatibility Conference (the “Participation”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its AlloSeq* portfolio or Participation; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023 and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
